The primary purpose of this study is to find the highest dose of the investigational drug LEE011 that can be safely given to patients with advanced solid tumors or lymphoma, and to learn about the side effects that might occur following treatment. The study may also indicate how the drug works in cancer patients, and if possible, how effective it might be in treating certain types of cancer. LEE011 is taken orally (by mouth).
LEE011 blocks the activity of two enzymes called cyclin D kinases 4 and 6 (CDK4/6). These enzymes are part of a pathway known to regulate cell growth. Blocking the activity of CDK 4/6 prevents some cancer cells from being able to make a new copy of their DNA. As a result, they cannot divide and may enter into a process called programmed cell death. Researchers hope LEE011 will slow the growth of cancer cells and lead to their death.